Daniel A. Goldstein, MD

This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1–positive lung cancer could save nearly $1 billion in US healthcare costs.

Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.